Current treatment options and response rates in children with chronic hepatitis C

Table 1 Sustained viral response in five representative prospective trials using polyethylene glycol-interferon alpha-2b and polyethylene glycol-interferon alpha-2a in combination with ribavirin and stratified for different clinical and laboratory parameters and genotypes, published between 2005 and 2011

	Wirth 20051	Jara 20081	Wirth 20101	Total PEG-interferon a-2b trials	Schwarz 20112	Sokal 20102	Total all trials
Dosage	1.5 μg/kg per week	1.0 μg/kg per week	60 μg/m² per week		180 μg/1.73 m²per week	100 μg/m² per week
Total (%)	36/61 (59)	15/30 (50)	70/107 (65.4)	121/198 (61.1)	29/55 (53)	43/65 (66.1)	193/318 (60.7)
Genotype (%)
1	22/46 (48)	12/26 (46)	38/72 (53)	72/144 (50)	21/45 (47)	27/47 (59)	120/236 (51)
2/3	13/13 (100)	3/3 (100)	28/30 (93)	44/46 (96)	8/10 (80)	16/17 (94)	68/73 (93)
4	1/2	0/1	4/5 (80)	5/8 (62)		Included in G1
ALT-levels (%)
Elevated	12/25 (48)		27/44 (61)			19/33 (58)	58/102 (57)
Normal	24/36 (67)		42/63 (67)			24/30 (80)	90/129 (70)
Mode of infection (%)
Parenteral	19/27 (70)	7/9 (78)	5/5 (100)	31/41(76)
Genotype 1	13/21 (62)		1/1
Vertical	12/25 (48)	8/21 (38)	46/75 (61)	66/121 (55)
Genotype 1	7/20 (35)		26/52 (50)	33/72 (46)
Break through	9.8%				6/41 (15)
Relapse	7.7%		8%		6/35 (17)

ALT: Alanine aminotransferase; PEG: Polyethylene glycol.

¹PEG-interferon α-2b;

²PEG-interferon α-2a.